Sandoz Resolves Patent Dispute with Regeneron, Clearing Path for Eylea Biosimilar Launch by 2026
核心洞察
Sandoz secured a patent settlement with Regeneron in September 2025, clearing legal hurdles for its FDA-approved aflibercept biosimilar Enzeevu (搜索)™ to launch by end of 2026.
The resolution positions Sandoz advantageously in the competitive $4.767 billion U.S. aflibercept market, where multiple biosimilars are vying for share against Regeneron's Eylea.
Enzeevu (搜索)'s interchangeable designation allows automatic pharmacy substitution, potentially enabling premium pricing compared to competitors like Amgen's Pavblu which launched with 10% discount.
Sandoz has successfully resolved its patent litigation with Regeneron in September 2025, clearing a critical legal obstacle for the commercial launch of its FDA-approved aflibercept biosimilar, Enzeevu (搜索)™. The settlement enables Sandoz to enter the highly competitive U.S. aflibercept market by the end of 2026 or potentially earlier under specific conditions, positioning the company to capture significant market share in a therapeutic category valued at $4.767 billion.
Strategic Advantage Through Early Settlement
The resolution marks a pivotal moment for Sandoz in the increasingly crowded aflibercept biosimilar landscape. Unlike competitors such as Biocon, which resolved its litigation in early 2025 but faces a delayed launch until late 2026, Sandoz's earlier settlement provides a temporal advantage that could prove crucial for market penetration.
Regeneron's aggressive litigation strategy had previously delayed Sandoz's market entry for over a year despite FDA approval of Enzeevu (搜索)™ in August 2024. The dispute involved 46 patents, with Regeneron's focus on the '865 patent covering aflibercept formulation specifications creating significant barriers to biosimilar launches across the industry.
"Regeneron's litigation tactics have created a 'chilling effect' on market entry, with developers facing average delays of 18–24 months post-FDA approval," according to a report by Big Molecule Watch. For Sandoz, the prolonged litigation represented dual risks of mounting legal costs and reputational damage from extended delays.
Competitive Market Dynamics
The U.S. aflibercept biosimilar market features five FDA-approved or advanced-stage products: Enzeevu (搜索) (Sandoz), Opuviz (Samsung Bioepis (搜索)), Ahzantive (Formycon (搜索)), Yesafili (Biocon), and Pavblu (Amgen). However, patent litigation has significantly delayed commercialization across the segment.
Amgen's Pavblu, which launched in 2024 with a 10% price discount relative to Eylea, has set early pricing benchmarks for the category. Despite multiple approved biosimilars, Eylea's U.S. sales remain resilient at $3.2 billion annually, with biosimilars capturing less than 5% market share as of Q3 2024, according to FiercePharma data.
The fragmented launch timeline has created a paradox where multiple entrants theoretically drive down prices, but overlapping litigation and staggered market entries prevent meaningful competition from emerging.
Interchangeability Advantage
Enzeevu (搜索)'s designation as interchangeable with Eylea provides Sandoz with a significant competitive advantage. This regulatory distinction allows pharmacists to automatically substitute Enzeevu for Eylea without prescriber intervention, potentially enhancing adoption rates and enabling pricing closer to the reference product compared to competitors offering steeper discounts.
The interchangeability status could prove particularly valuable as healthcare systems increasingly focus on cost containment while maintaining therapeutic efficacy. This positioning may allow Sandoz to command premium pricing relative to other biosimilars in the category.
Market Growth Projections
The U.S. biosimilar market is projected to grow at a compound annual growth rate of 9.1% from 2026 to 2033, reaching $3.2 billion by 2033. This growth trajectory is driven by cost-conscious healthcare systems and expanding regulatory support for biosimilar adoption.
The global biosimilar market is expected to expand from $34.8 billion in 2024 to $93.1 billion by 2030, reinforcing the strategic importance of early market positioning in key therapeutic categories like aflibercept.
Investment Implications
The settlement resolution addresses three critical risks that have plagued biosimilar developers: prolonged litigation costs, regulatory scrutiny, and market saturation concerns. Sandoz's $150 million investment in Enzeevu (搜索)™ development, previously facing indefinite deferral due to litigation, can now progress toward commercial returns.
The resolution also demonstrates Sandoz's legal agility in navigating complex patent disputes, potentially serving as a blueprint for future biosimilar launches and reinforcing the company's position as a leader in complex biologics development.
However, challenges remain, including ongoing litigation in Australia where Sandoz plans to launch a different aflibercept biosimilar, Afqlir®, highlighting the global complexity of patent disputes in the biosimilar space.